热门话题-美国食品药品监督管理局（FDA）加快迷幻药物研究，Compass Pathways股价应声上涨

路透中文

Apr 24

热门话题-<a href="https://laohu8.com/S/USFD">美国食品</a>药品监督管理局（FDA）加快迷幻药物研究，Compass Pathways股价应声上涨

4月24日 - ** Compass Pathways CMPS.O 股价上涨 5.52%，报 9.66 美元

** 美国食品药品监督管理局（FDA）周五表示，将采取措施 (link)，以加快针对严重精神疾病的新疗法的研发进程，此举是响应唐纳德·特朗普总统签署的一项行政命令

** 该行政命令于周六签署，旨在加快基于迷幻药的医学研究和治疗的普及

** FDA表示将向三家开发迷幻药物疗法的公司发放特别优先券

** 其他迷幻药物开发商Enveric Biosciences ENVB.O 上涨3.36%，Cybin HELP.O 在美上市的股票上涨6.26%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2629842135"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629842135\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629842135?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-04-24 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629842135","market":"hk","top_or_hot":-1,"title":"热门话题-美国食品药品监督管理局（FDA）加快迷幻药物研究，Compass Pathways股价应声上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>热门话题-<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品监督管理局（FDA）加快迷幻药物研究，Compass Pathways股价应声上涨</title></head><body><p>\n<span>4月24日</span><span> - </span>** Compass Pathways <span>CMPS.O</span> 股价上涨 5.52%，报 9.66 美元</p><p>** 美国<span>食品药品监督管理局 </span>（<span>FDA） </span>周<span>五表示， </span>将采取措施 (<span>link</span>)，以加快针对严重精神疾病的新疗法的研发进程，此举是响应唐纳德·特朗普总统签署的一项行政命令</p><p>** 该行政命令于周六签署，旨在加快基于迷幻药的医学研究和治疗的普及</p><p>** FDA表示将向三家开发迷幻药物疗法的公司发放特别优先券</p><p>** 其他迷幻药物开发商<a href=\"https://laohu8.com/S/ENVB\">Enveric Biosciences</a> <span>ENVB.O</span> 上涨3.36%，Cybin <span>HELP.O</span> 在美上市的股票上涨6.26%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>热门话题-美国食品药品监督管理局（FDA）加快迷幻药物研究，Compass Pathways股价应声上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n热门话题-美国食品药品监督管理局（FDA）加快迷幻药物研究，Compass Pathways股价应声上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-04-24 21:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>热门话题-<a href=\"https://laohu8.com/S/USFD\">美国食品</a>药品监督管理局（FDA）加快迷幻药物研究，Compass Pathways股价应声上涨</title></head><body><p>\n<span>4月24日</span><span> - </span>** Compass Pathways <span>CMPS.O</span> 股价上涨 5.52%，报 9.66 美元</p><p>** 美国<span>食品药品监督管理局 </span>（<span>FDA） </span>周<span>五表示， </span>将采取措施 (<span>link</span>)，以加快针对严重精神疾病的新疗法的研发进程，此举是响应唐纳德·特朗普总统签署的一项行政命令</p><p>** 该行政命令于周六签署，旨在加快基于迷幻药的医学研究和治疗的普及</p><p>** FDA表示将向三家开发迷幻药物疗法的公司发放特别优先券</p><p>** 其他迷幻药物开发商<a href=\"https://laohu8.com/S/ENVB\">Enveric Biosciences</a> <span>ENVB.O</span> 上涨3.36%，Cybin <span>HELP.O</span> 在美上市的股票上涨6.26%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL4T4171D7:1","article_id":"2629842135","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629842135","pubTimestamp":1777037946,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","CMPS":"COMPASS Pathways plc","ENVB":"Enveric Biosciences"},"translate_title":"Hot Topics-Compass Pathways Stock Rises as Food and Drug Administration (FDA) Speeds Up Psychedelic Research","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENVB":0.9,"CMPS":0.9},"content_text":"热门话题-美国食品药品监督管理局（FDA）加快迷幻药物研究，Compass Pathways股价应声上涨\n4月24日 - ** Compass Pathways CMPS.O 股价上涨 5.52%，报 9.66 美元** 美国食品药品监督管理局 （FDA） 周五表示， 将采取措施 (link)，以加快针对严重精神疾病的新疗法的研发进程，此举是响应唐纳德·特朗普总统签署的一项行政命令** 该行政命令于周六签署，旨在加快基于迷幻药的医学研究和治疗的普及** FDA表示将向三家开发迷幻药物疗法的公司发放特别优先券** 其他迷幻药物开发商Enveric Biosciences ENVB.O 上涨3.36%，Cybin HELP.O 在美上市的股票上涨6.26%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}